<DOC>
	<DOCNO>NCT02699515</DOCNO>
	<brief_summary>The main purpose study assess safety tolerability MSB0011359C . Study consist dose-escalation part expansion part subject metastatic locally advanced solid tumor , standard effective therapy exist standard therapy fail .</brief_summary>
	<brief_title>MSB0011359C ( M7824 ) Subjects With Metastatic Locally Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Able willing give write informed consent sign appropriate write informed consent form ( ICF ) , prior performance trial activity Eligible male female subject age great equal ( &gt; = ) 20 year Histologically cytologically proven metastatic locally advanced solid tumor , effective standard therapy exist standard therapy fail Eastern Cooperative Oncology Group performance status ( ECOG ) performance status 0 1 trial entry Life expectancy &gt; =12 week judge Investigator . Adequate hematological function define white blood cell ( WBC ) count &gt; =3*10^9/Liter absolute neutrophil count ( ANC ) &gt; =1.5*10^9/Liter , lymphocyte count &gt; =0.5* 10^9/Liter , platelet count &gt; =75*10^9/Liter , Hemoglobin ( Hgb ) &gt; = 9 gram per deciliter ( g/dL ) ( absence blood transfusion ) . Adequate hepatic function define total bilirubin level &lt; =1.5 × Upper limit normal ( ULN ) , AST level &lt; = 2.5 × ULN , ALT level &lt; = 2.5 × ULN . Adequate renal function define estimate creatinine clearance &gt; 50 milliliter per minute ( mL/min ) accord CockcroftGault formula measure creatinine clearance 24 hour urine collection . Other protocoldefined exclusion criterion could apply . Concurrent treatment nonpermitted drug intervention Anticancer treatment within 28 day start trial treatment , example cyto reductive therapy , radiotherapy ( exception palliative bone direct radiotherapy ) , immune therapy , cytokine therapy Major surgery within 28 day start trial treatment ( exclude prior diagnostic biopsy ) Systemic therapy immunosuppressive agent within 7 day start trial treatment ; use investigational drug within 28 day start trial treatment Previous malignant disease target malignancy investigate trial exception cervical carcinoma situ superficial non invasive bladder cancer ( treat curative intent ) within last 5 year basal cell squamous cell carcinoma situ within last 3 year Rapidly progressive disease , opinion Investigator , may predispose inability tolerate treatment trial procedure Active history central nervous system metastasis , except melanomaspecific Central nervous system ( CNS ) criterion list Receipt organ transplantation , include allogeneic stemcell transplantation , exception transplant require immunosuppression ( eg , corneal transplant , hair transplant )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>MSB0011359C</keyword>
</DOC>